Successful management of an arteriovenous malformation with trametinib in a patient with capillary‐malformation arteriovenous malformation syndrome and cardiac …
CL Nicholson, S Flanagan, M Murati… - Pediatric …, 2022 - Wiley Online Library
CL Nicholson, S Flanagan, M Murati, C Boull, E McGough, R Ameduri, B Weigel…
Pediatric Dermatology, 2022•Wiley Online LibraryCapillary malformation‐arteriovenous malformation (CM‐AVM) syndrome is an autosomal
dominant condition characterized by multifocal, noncontiguous pink patches on the skin that
often have a surrounding pale halo. In some cases, an association with a fast flow,
arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16‐
year‐old woman with CM‐AVM syndrome and significant cardiac compromise successfully
treated with trametinib, a mitogen‐activated protein kinase (MEK) inhibitor.
dominant condition characterized by multifocal, noncontiguous pink patches on the skin that
often have a surrounding pale halo. In some cases, an association with a fast flow,
arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16‐
year‐old woman with CM‐AVM syndrome and significant cardiac compromise successfully
treated with trametinib, a mitogen‐activated protein kinase (MEK) inhibitor.
Abstract
Capillary malformation‐arteriovenous malformation (CM‐AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16‐year‐old woman with CM‐AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen‐activated protein kinase (MEK) inhibitor.
Wiley Online Library